Bio News

Amgen said its antibody drug daksdilimab reduced disease severity in a Phase 2 trial involving 72 patients with discoid lupus. The low-dose group had a 6-point reduction in skin lupus severity scores compared with the placebo group. Amgen is moving the antibody into the registration-trial stage.

BIOBOOK TEAM
biobookmedia@biobook.co.krDaewoong Pharmaceutical’s Flodicitinib Achieves More Than 90% Target Occupancy in Phase 1 Trial
Aribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug